Cargando…

Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock

Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial source of morbidity and mortality despite advances in recognition and treatment. Prior to the advent of percutaneous and more durable left ventricular support devices, prompt revascularization with the add...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalal, Pratik K., Mertens, Amy, Shah, Dinesh, Hanson, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364115/
https://www.ncbi.nlm.nih.gov/pubmed/30809398
http://dx.doi.org/10.1155/2019/4591250
_version_ 1783393203555139584
author Dalal, Pratik K.
Mertens, Amy
Shah, Dinesh
Hanson, Ivan
author_facet Dalal, Pratik K.
Mertens, Amy
Shah, Dinesh
Hanson, Ivan
author_sort Dalal, Pratik K.
collection PubMed
description Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial source of morbidity and mortality despite advances in recognition and treatment. Prior to the advent of percutaneous and more durable left ventricular support devices, prompt revascularization with the addition of vasopressors and inotropes were the standard of care in the management of this critical population. Recent published studies have shown that in addition to prompt revascularization, unloading of the left ventricle with the placement of the Impella percutaneous axillary flow pump can lead to improvement in mortality. Parameters such as the cardiac power output (CPO) and pulmonary artery pulsatility index (PAPi), obtained through pulmonary artery catheterization, can help ascertain the productivity of right and left ventricular function. Utilization of these parameters can provide the information necessary to escalate support to the right ventricle with the insertion of an Impella RP or the left ventricle with the insertion of larger devices, which provide more forward flow. Herein, we present a case of AMI complicated by cardiogenic shock resulting in biventricular failure treated with the percutaneous insertion of an Impella RP and Impella 5.0 utilizing invasive markers of left and right ventricular function to guide the management and escalation of care.
format Online
Article
Text
id pubmed-6364115
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63641152019-02-26 Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock Dalal, Pratik K. Mertens, Amy Shah, Dinesh Hanson, Ivan Case Rep Cardiol Case Report Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial source of morbidity and mortality despite advances in recognition and treatment. Prior to the advent of percutaneous and more durable left ventricular support devices, prompt revascularization with the addition of vasopressors and inotropes were the standard of care in the management of this critical population. Recent published studies have shown that in addition to prompt revascularization, unloading of the left ventricle with the placement of the Impella percutaneous axillary flow pump can lead to improvement in mortality. Parameters such as the cardiac power output (CPO) and pulmonary artery pulsatility index (PAPi), obtained through pulmonary artery catheterization, can help ascertain the productivity of right and left ventricular function. Utilization of these parameters can provide the information necessary to escalate support to the right ventricle with the insertion of an Impella RP or the left ventricle with the insertion of larger devices, which provide more forward flow. Herein, we present a case of AMI complicated by cardiogenic shock resulting in biventricular failure treated with the percutaneous insertion of an Impella RP and Impella 5.0 utilizing invasive markers of left and right ventricular function to guide the management and escalation of care. Hindawi 2019-01-23 /pmc/articles/PMC6364115/ /pubmed/30809398 http://dx.doi.org/10.1155/2019/4591250 Text en Copyright © 2019 Pratik K. Dalal et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Dalal, Pratik K.
Mertens, Amy
Shah, Dinesh
Hanson, Ivan
Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title_full Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title_fullStr Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title_full_unstemmed Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title_short Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
title_sort hemodynamic support using percutaneous transfemoral impella 5.0 and impella rp for refractory cardiogenic shock
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364115/
https://www.ncbi.nlm.nih.gov/pubmed/30809398
http://dx.doi.org/10.1155/2019/4591250
work_keys_str_mv AT dalalpratikk hemodynamicsupportusingpercutaneoustransfemoralimpella50andimpellarpforrefractorycardiogenicshock
AT mertensamy hemodynamicsupportusingpercutaneoustransfemoralimpella50andimpellarpforrefractorycardiogenicshock
AT shahdinesh hemodynamicsupportusingpercutaneoustransfemoralimpella50andimpellarpforrefractorycardiogenicshock
AT hansonivan hemodynamicsupportusingpercutaneoustransfemoralimpella50andimpellarpforrefractorycardiogenicshock